Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Monaldi Archives for Chest Disease is, therefore, E-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear in print on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors.

Monaldi Arch Chest Dis 2021 [Epub ahead of print]

Citation

Gender differences in vaccine therapy: where are we in COVID-19 pandemic?

Tiziana Ciarambino¹, Elena Barbagelata², Graziamaria Corbi³, Immacolata Ambrosino⁴, Cecilia Politi⁵, Franco Lavalle⁶, Anna Ruggieri⁷, Anna Maria Moretti⁸

¹Internal Medicine Department, Marcianise Hospital, ASL Caserta
²Department of Internal Medicine, Lavagna Hospital, Genoa
³Department of Medicine and Health Sciences, University of Molise, Campobasso
⁴Local Healthcare Unit of Bari, Health District 10, Post-acute Care Triggiano, Bari
⁵Head of Gender Medicine Area F.A.D.O.I., Internal Medicine Department, Isernia
⁶Vicepresident OMCEO (Provincial order of surgeons and dentists), Bari
⁷Center for Gender Specific Medicine, Istituto Superiore Sanità, Rome
⁸President of GISeg, Italian Group for Health and Gender, Bari, Italy

Corresponding Author: Tiziana Ciarambino, MD, PhD, Internal Medicine Department, Marcianise Hospital, ASL Caserta, Italy. E-mail: tiziana.ciarambino@gmail.com

Abstract

Vaccination is one of the greatest achievements of public health. Vaccination programs have contributed to the decline in mortality and morbidity of various infectious diseases. This review aims to investigate the impact of sex/gender on the vaccine acceptance, responses, and outcomes. The studies were identified by using PubMed, until 30th June 2020. The search was performed by using the following keywords: SARS-CoV-2, COVID-19, gender, sex, vaccine, adverse reaction. Clinical trials, retrospective and prospective studies were included. Studies written in languages other than English were excluded. Studies were included if gender differences in response to vaccination trials were reported. All selected studies were qualitatively analyzed. Innate recognition and response to viruses, as well as, adaptive immune responses during viral infections, differ between females and males. Unfortunately, a majority of vaccine trials have focused on healthy people, with ages between 18 to 65 years, excluding the elderly, pregnant women, post-menopausal female and children. In conclusion, it is apparent that the design of vaccines and
vaccine strategies should be sex-specific, to reduce adverse reactions in females and increase immunogenicity in males. It should be mandatory to examine sex-related variables in pre-clinical and clinical vaccine trials, such as their crucial role for successful prevention of pandemic COVID-19.

**Keywords:** Gender and/or sex differences, vaccine, adverse reaction, COVID-19, SARS-CoV-2

**Authors’ contributions:** TC study conception and design, revision of all clinical trials, manuscript drafting. TC, IA, EB, GMC revision of all clinical trials, critical revision. AR, CP, FL, AMM study conception and design, critical revision. All authors read and approved the final version of the manuscript.

**Conflict of interest:** The authors declare that they have no conflict of interest related to the subject matter or materials discussed in this article.

**Introduction**

Vaccination is one of the greatest achievements of public health. Vaccination programs have contributed to the decline in mortality and morbidity of various infectious diseases [1]. To be successful in reducing the prevalence and incidence of vaccine-preventable diseases (VPD), vaccination programs rely on a high uptake level. In addition to direct protection for vaccinated individuals, high vaccination coverage rates induce indirect protection for the overall community, or herd immunity, by slowing transmission of VPD, thereby decreasing the risk of infection among those who remain susceptible in the community [2]. However, these national estimates may hide clusters of under-vaccinated individuals [3]. It is estimated that less than 5–10% of individuals have strong anti-vaccination convictions [4]. However, a more significant proportion could be categorized as being hesitant regarding vaccination [5]. In particular, sex and gender-related factors, impact vaccine acceptance, responses, and outcomes. Sex (i.e., the biological differences between males and females) and gender (i.e., cultural norms associated with being male or female) impact acceptance of, responses to, and the outcome of vaccination [6]. Female individuals are often less likely to accept vaccines, but once vaccinated, develop higher and longer-lasting protective antibody responses, as compared to males [6]. However, they undergo adverse events
more often and intense than male vaccines [6]. The mechanisms underlying sex differences in response to vaccination include sex hormone modulation of the immune system as well as genetic and epigenetic regulation. It has been reported that the immune response to the monovalent 2009 H1N1 vaccine, was partly due to reproductive senescence in females, in which higher circulating estradiol concentrations are associated with greater antibody responses to the vaccine [7]. Although there are distinct effects of sex steroid hormones on immune responses, including responses to vaccines, the lack of age-related changes in the sex differential effects of vaccines suggests that genetic or other factors are likely to be involved. This review aims to investigate the impact of sex/gender on the vaccine acceptance, responses, and outcomes.

Methods
The studies were identified by using the PubMed database, published until 30th June 2020. The search was performed by using the following keywords: SARS-CoV-2, COVID-19, gender, sex, vaccine, adverse reaction. Clinical trials, retrospective, and prospective studies were included. Three authors (TC, EB, IA) reviewed all study abstracts. Studies were included if gender differences in response to the vaccine were reported. Studies written in languages other than English were excluded. All selected studies were qualitatively analyzed.

Results
Vaccine and gender
In our previous review, we underlined that the reduced susceptibility of females to viral infections could be attributed to the protection from the X chromosome and sex hormones, which play an essential role in innate and adaptive immunity [8]. In particular, it has been reported that the innate immune response to viruses, as well as adaptive immune responses during viral infections, differ between females and males [7]. Adult females develop higher antibody responses to vaccines than males. After either childhood or adult vaccination against influenza, yellow fever, rubella, measles, mumps, hepatitis A and B, herpes simplex 2, rabies, dengue viruses, protective antibody responses can be twice as high in females compared to males of all ages [6].
In this regard, several studies have illustrated that females, generally have greater inflammatory and humoral immune responses, than males, during viral infections [7] (Figure 1). These responses contribute to better clearance of viruses, including SARS-CoV-2, in female subjects. To this regard, in COVID-19 infection, cytokine response is higher in ARDS male patients. A study of 331 Chinese patients, with confirmed SARS-CoV-2 infection, reported the anti-SARS-CoV-2 immunoglobulin G (IgG) responses were related to the severity of the disease. The sex distribution of recovering cases was 36% and 65% for men and women, respectively [9]. Interestingly, the anti–SARS-CoV-2 IgG titers were similar between sexes in patients with mild COVID-19 disease. In patients with severe disease, the female subjects exhibited a higher antibody response, than men, with the production of antibodies at earlier phases of the disease. These results were also consistent with other studies describing higher antibody levels (including more functional antibodies) in adult females compared to adult males [7]. The more intense immune responses in women predispose female subjects to autoimmune diseases, and to experience more adverse reactions to the vaccine [11]. Some of these differences can be linked to hormonal differences, such as estrogen and testosterone levels [10]. It has been reported that testosterone reduces vaccination response [12].

In a randomized, prospective, single-blind study on humoral immune responses in an inactivated influenza vaccine (TIV), Beyer et al. reported that healthy women (18–64 years of age) generate a more robust protective antibody response. The response of female to a half dose of the influenza vaccine, was equivalent to the antibody response of men to the full dose [13], thus posing the basis for a sex-personalized vaccine dosage.

One possible explanation of the more intense, and sometimes, longer-lasting immune responses in women is because females have two X chromosomes, while men only one. Since the X chromosome is enriched by genes encoding immune factors (such as Toll-like Receptor-7 [TLR7], interleukins, and chemokines) as regulatory molecules like microRNAs, there is an overexpression of immune-related molecules in female subjects compared to males.

Age is another factor that induces the modification of immune response and it should also not be forgotten. In this regard, with aging, there is a progressive functional decline in the immune system [14]. One of the most well-characterized attributes of an aging immune system is an aberrant chronic low-grade pro-inflammatory state, which may occur to a greater extent in females than in males [15]. Moreover, Wang et al. evidenced that, in older women, influenza vaccination has been associated with lower hospitalization and mortality rates compared to men, suggesting that females
maintain higher titers of hemagglutination inhibition (HAI) assay, or respond more effectively to vaccination, thereby experiencing better protection in comparison to men [16].

Results

COVID-19 vaccine and gender

There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to control the COVID-19 pandemic. Coronavirus vaccines, in animal models that mimic human disease, have been immunogenic but generally not shown to effectively prevent the disorder [17]. Previous use of coronavirus vaccines (SARS-CoV and MERS-CoV) in some animal models raised safety concerns regarding Th2 mediated immunopathology [18]. As of 1st June 2020, there are currently 124 candidate vaccines that are under development for prevention of COVID-19 disease, listed by the WHO Health Organization [19] of which 10 candidate vaccines, specifically designed for the prevention of COVID-19 have entered phase 1, combined phase 1/2 or phase 2 human clinical trials in adults. Most of these trials are enrolling healthy adults (from age 18 to 55 years) only, with the upper age limit of inclusion ranging from 50 to 60 years. Two trials are enrolling young participants, one from aged ≥3 years and the other ≥6 years with no upper age limit in both. One combined phase I/II trial includes older adults (up to age 85 years), while another early phase I, been extended in May 2020 to include also older adults (to age 99 years) [20]. Unfortunately, a majority of vaccine trials have focused on healthy people, between the ages of 18-65 years, excluding the elderly, pregnant women, post-menopausal females and children. In this regard, it is suggested that post-menopausal female will need a tailored vaccine dose, to contrast their susceptibility to infectious diseases once their estrogen levels decline [21]. Therefore, given the disproportionate mortality rate by gender in people over the age of 60, the elderly and gender need to be considered in vaccine trials to ensure safety, immunogenicity and efficacy. Vaccine efficacy in under-represented (female subjects for example) and vulnerable populations (older population for example) also remains an issue. An important point to be considered comes from the recently disclosed preliminary results of two ongoing COVID-19 vaccine clinical trials [22] reporting that the population under study included male and female subjects. However, the published results about safety and immunogenicity are not stratified by sex, thus probably underestimating the adverse effects in women and the sex-specific immunogenic response.
Discussion

Males and females are biologically different, and this fact likely contributes to sex-specific vaccine outcomes. Among children, adults and older adults, females develop higher antibody responses and experience more adverse reactions to vaccines than males. In particular, the elderly may represent a specific cluster of high-risk patients for developing COVID-19 with rapidly progressive clinical deterioration. Indeed, in older individuals, immunosenescence and comorbid disorders are more likely to promote viral-induced cytokine storm resulting in life-threatening respiratory failure and multisystemic involvement [23]. Although there are distinct effects of sex steroid hormones on immune responses, including responses to vaccines, the lack of age-related changes in the sex differential effects of vaccines suggests that genetic or other factors are likely to be involved. In this global health emergency, the vaccine is needed, considering the role of sex in vaccine response and adverse reactions. It is crucial that gender is considered in clinical trials for COVID-19 vaccines-development to include the analyses of efficacy, vaccine response and adverse reactions. In our review, we analyzed clinical trials, which evaluated immune responses by gender. In all the analyzed studies, we did not find data disaggregated by sex and age, related to effectiveness, adverse reactions and vaccine response. Current pandemic stressed the importance to allowing a large access to highly attractive investigational drugs in international programs and to authorize a more rapid extension of the approved drugs indications as performed in clinical settings other than COVID-19 [24].

As reported for other treatment, each patient is unique, so we can’t think to gain the same response for everyone. For this reason, it is crucial to collect and analyze sex-disaggregated data, to test and identify, specific prophylactic and treatment measures. It is urgently needed to obtain a gender-specific preventive intervention by vaccination based on personalized vaccination. In conclusion, sex/gender variables should be considered in preclinical and clinical vaccine trials as a crucial role in the successful prevention of the COVID-19 pandemic.

References

15. Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology (Bethesda) 2015;30:408-16.
21. Cutolo M, Smith V, Paolino S. Understanding immune effects of oestroges to explain the

Figure 1. Sex differences in response to viral infections.

Sex disparity